Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Nature is full of untapped potential. Microbes are a proven but underused resource...
Nature is full of untapped potential. Microbes ...
Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncolo...
Spectrum Pharmaceuticals is a leading biotechno...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company ...
Innovate is a publicly traded (Nasdaq: INNT) cl...
Vir integrates diverse innovations in science, technology, and medicine to transfo...
Vir integrates diverse innovations in science, ...
We are a biotechnology company focused on delivering transformational therapies fo...
We are a biotechnology company focused on deliv...
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...
Phio Pharmaceuticals is focused on developing t...
Join the National Investor Network and get the latest information with your interests in mind.